

Microviable Therapeutics announces Research Collaboration with Venter Pharma and Inmunomet Intolerancia y Disbiosis

Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL and Inmunomet Intolerancia y Disbiosis SL to assist on the development of novel diagnostics tools for intestinal diseases.

“We are excited about this collaboration with tremendous potential combining Venter Pharma diagnostics platform, Inmunomet clinical expertise and Microviable microbiome pipeline, to develop novel molecular diagnostic tools for various intestinal diseases”, said Claudio Hidalgo Cantabrana, PhD, Microviable’s CEO. The current diagnostic tools for some intestinal disorders are not specific nor reliable with many false results that prevent from proper patient diagnostic and subsequent medical care.

We look forward to working with both partners to develop novel and accurate molecular diagnostics solutions that can save time and improve patients’ diagnostics, the first and more important step in medical care.

Contact:

Claudio Hidalgo Cantabrana, PhD

984088384

info@microviable.com